Back to Newsroom

StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial

NEWARK, CA, June 19, 2014 (GLOBE NEWSWIRE) – StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company’s proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.

Click here to read more